Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.73 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | DAO | P14920 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | PHGDH | O43175 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16599480 | 0.86 | MCL1 (0.76) | MCL1SLC9A1MAPTDAOMEN1 | |
| SCHEMBL117186 | 0.85 | MCL1 (1.00) | MCL1SLC9A1MAPTDAOMEN1 | |
| SCHEMBL2323444 | 0.83 | MCL1 (0.71) | MCL1SLC9A1MAPTDAOMEN1 | |
| Hydrochloric Acid SCHEMBL8600262 | 0.83 | MCL1 (0.96) | MCL1SLC9A1MAPTDAOMEN1 | |
| SCHEMBL2322980 | 0.83 | MCL1 (0.71) | MCL1SLC9A1MAPTDAOMEN1 | |
| SCHEMBL5748064 | 0.83 | MCL1 (0.71) | MCL1SLC9A1MAPTDAOMEN1 | |
| SCHEMBL10350688 | 0.81 | MCL1 (0.69) | MCL1SLC9A1MAPTDAOMEN1 | |
| SCHEMBL27467673 | 0.81 | MCL1 (0.74) | MCL1SLC9A1MAPTDAOMEN1 | |
| Potassium Ion SCHEMBL15876031 | 0.81 | MCL1 (0.69) | MCL1SLC9A1MAPTDAOMEN1 | |
| Hydrochloric Acid SCHEMBL28264080 | 0.81 | MCL1 (0.69) | MCL1SLC9A1MAPTDAOMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250120948-A1 | Small Molecules G(alpha)I2 Inhibitors and Combination With Anticancer Drugs and Use Thereof | CLARK ATLANTA UNIVERSITY | 2025-04-17 | — | — | US | disclosed |
| EP-3356387-B1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | UNIV MONASH (AU) | 2024-06-26 | — | — | EP | disclosed |
| US-20230364053-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER | TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY (JP) | 2023-11-16 | — | — | US | disclosed |
| EP-3954681-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-3402790-B1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-10-06 | — | — | EP | disclosed |
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-04-30 | — | — | US | disclosed |
| EP-3521292-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | Pfizer Inc (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-2884981-B1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2018-06-20 | — | — | EP | disclosed |
| US-7163937-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| CN-1345724-A | Indolylpiperidine compound and preparation process and use thereof | SHANGHAI PHARMACEUTICAL INST C (CN) | 2002-04-24 | — | — | CN | disclosed |
| EP-0279263-B1 | INDOLE, BENZOFURAN, BENZOTHIOPHENE CONTAINING LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1993-08-04 | — | — | EP | disclosed |
| EP-0291172-B1 | KETONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1992-11-19 | — | — | EP | disclosed |
| US-5084474-A | Antagonist of 5-hydroxytryptamine receptors on nerves and useful for treatment of psychotic disorders, anxiety, and nausea and vomiting, compounds of imidazole | GLAXO GROUP LIMITED (GB) | 1992-01-28 | — | — | US | disclosed |
| US-5019586-A | 5-Hydroxytryptamine Receptor Antagonists | GLAXO GROUP LIMITED | 1991-05-28 | — | — | US | disclosed |
| US-4918080-A | ANXIOLYTIC AGENTS, ANTIEMETICS | GLAXO GROUP LIMITED (GB) | 1990-04-17 | — | — | US | disclosed |
| US-4873259-A | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1989-10-10 | — | — | US | disclosed |
| EP-0291172-A1 | Ketone derivatives | GLAXO GROUP LIMITED (GB) | 1988-11-17 | — | — | EP | disclosed |
| EP-0279263-A2 | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | ROCK1, MYLK, RHOA | MCL1 2807/4885SLC9A1 269/4885MAPT 280/4885 |
| US-20230364053-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER | AR, NR5A1, CYP17A1 | MCL1 4399/4885SLC9A1 380/4885MAPT 1261/4885 |
| US-20250120948-A1 | Small Molecules G(alpha)I2 Inhibitors and Combination With Anticancer Drugs and Use Thereof | GDI2, GNAI2, GNAI3 | MCL1 1450/4885SLC9A1 3122/4885MAPT 4818/4885 |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | MCL1 2807/4885SLC9A1 269/4885MAPT 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.